Company name
2022Founder
alex rubinsteyn Alexander Rubinsteyn, PhD, is a UNC Lineberger research member working on applications of machine learning, genomics and computational immunology to therapeutic cancer vaccine design. He has helped design and run several early stage clinical trials of neoantigen vaccines.
PhD in Computer Science